(Total Views: 306)
Posted On: 01/23/2017 10:51:51 AM
Post# of 72447
We've all been slimed by this latest offering from AF. I had forgotten that he was involved in the AVXL take-down.
By the way, AVXL's market cap is 167.5 million. They have a novel drug that's in a (promising) clinical trial for Alzheimer's -- they are not going down the same pathways as the many failed drugs. They're also going to try it for Parkinson's and other diseases. But, it is tremendously risky, they will either go up hugely or go bankrupt depending on the results of their clinical trial. (I own some AVXL stock and options.)
Compare that to CTIX's market cap of about 135 million, for 3 totally different drugs in 5 clinical trials, and all trials thus far have been successful. Someone want to tell me how this conforms to "efficient market theory"?
By the way, AVXL's market cap is 167.5 million. They have a novel drug that's in a (promising) clinical trial for Alzheimer's -- they are not going down the same pathways as the many failed drugs. They're also going to try it for Parkinson's and other diseases. But, it is tremendously risky, they will either go up hugely or go bankrupt depending on the results of their clinical trial. (I own some AVXL stock and options.)
Compare that to CTIX's market cap of about 135 million, for 3 totally different drugs in 5 clinical trials, and all trials thus far have been successful. Someone want to tell me how this conforms to "efficient market theory"?
(2)
(0)
